biostudies-literatureUnknown14(3)Ghasemi DRMedulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic strategies are needed to increase survival rates and to reduce treatment-related toxicity. We performed a noncomprehensive targeted review of the current clinical trial landscape and literature to summarize innovative treatment options for non-WNT/non-SHH medulloblastoma. A multitude of new drugs is currently evaluated in trials for which non-WNT/non-SHH patients are eligible, for instance immunotherapy, kinase inhibitors, and drugs targeting the epigenome. However, the majority of these trials is nCancers679https://www.ebi.ac.uk/biostudies/studies/S-EPMC8833659biostudies-literatureThe Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.PMC8833659Fleischhack GPajtler KWGhasemi DRMilde TfalseThe Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.Medulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic strategies are needed to increase survival rates and to reduce treatment-related toxicity. We performed a noncomprehensive targeted review of the current clinical trial landscape and literature to summarize innovative treatment options for non-WNT/non-SHH medulloblastoma. A multitude of new drugs is currently evaluated in trials for which non-WNT/non-SHH patients are eligible, for instance immunotherapy, kinase inhibitors, and drugs targeting the epigenome. However, the majority of these trials is n2022-01-01T00:00:00Z2022 Jan2025-04-04T07:55:05.949Z2025-02-19T05:04:43.922ZS-EPMC88336593515894710.3390/cancers14030679